Di Cosimo, Serena <br/><br/>
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.  [electronic resource] 

 -  European journal of cancer (Oxford, England : 1990)  09 2019 
 - 1-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-0852 
<br/><br/><label>Standard No.: </label>10.1016/j.ejca.2019.06.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Immunological--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Biomarkers, Tumor--genetics<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Clinical Decision-Making<br/>Clinical Trials, Phase III as Topic<br/>Female<br/>Gene Expression Profiling<br/>Humans<br/>Lapatinib--adverse effects<br/>Multicenter Studies as Topic<br/>Neoadjuvant Therapy<br/>Patient Selection<br/>Precision Medicine<br/>Predictive Value of Tests<br/>Protein Kinase Inhibitors--adverse effects<br/>Randomized Controlled Trials as Topic<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Retrospective Studies<br/>Risk Factors<br/>Time Factors<br/>Transcriptome<br/>Trastuzumab--adverse effects<br/>Treatment Outcome